In addition, anti-E6/E7 siRNA coupled with anti-epidermal growth factor receptor (EGFR) antibodies delivered via targeted lipid-based nanoparticles (tLNPs) have shown successful antitumor effects in a xenograft HR-HPV HNSCC model [84]. Here, EGFR is linked to head and neck squamous cell carcinoma.